Everolimus

Small molecule

Also known as RAD001

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy, HR+/HER2- Metastatic Breast Cancer, Breast Cancer, Renal Cell Carcinoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (5)
US
  • Hormone Receptor-Positive, HER2-Negative Breast Cancer AFINITOR ® is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole.
  • Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma AFINITOR is indicated for the treatment of adult patients with renal angiomyolipoma and TSC, not requiring immediate surgery.Outside this platform's coverage
  • Neuroendocrine Tumors (NET) AFINITOR is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. AFINITOR is indicated for the treatment of adult patients with progressive, well-differentiated, non-functional NET of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease.
    Outside this platform's coverage
  • Adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resectedOutside this platform's coverage
Product first approved 2009FDA label
EU
  • Afinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women
Product first approved 2009EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (82)
Breast Cancer
NCT07407517 · Fudan University
2026-02-01 – 2033-02-01 · Breast Cancer Females, Triple Negative Breast Cancer (TNBC)
What this study did
NCT01805271 · UNICANCER
2013-03 – 2030-06 · Primary Non-metastatic Breast Cancer, Who Remain Disease-free
What this study did
NCT05954442 · Fudan University
2023-09-13 – 2026-08 · Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation
What this study did
NCT05429684 · First Affiliated Hospital Xi'an Jiaotong University
2021-01-01 – 2024-02-28 · HER2+ Breast Cancer
What this study did
NCT00876395 · Novartis Pharmaceuticals
2009-09-10 – 2017-10-23 · Breast Cancer
What this study did
NCT00567554 · GBG Forschungs GmbH
2007-10 – 2015-10 · Breast Cancer
What this study did
Epilepsy
HR+/HER2- Metastatic Breast Cancer
NCT01674140 · SWOG Cancer Research Network
2013-09-12 – 2030-01 · Breast Cancer
What this study did
NCT06680921 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2024-11-14 – 2028-08-31 · Locally Advanced or Metastatic Breast Cancer
What this study did
NCT06382948 · MedSIR
2024-12-05 – 2028-04 · Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
What this study did
NCT05306340 · Genentech, Inc.
2022-08-03 – 2027-06-15 · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
What this study did
NCT02137837 · SWOG Cancer Research Network
2014-05 – 2019-12-31 · Breast Cancer
What this study did
NCT02404051 · Consorzio Oncotech
2015-12 – 2019-01 · Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Locally Advanced Malignant Neoplasm
What this study did
NCT01007942 · Novartis Pharmaceuticals
2009-10 – 2015-06 · HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT01773460 · GBG Forschungs GmbH
2013-07 – 2014-07 · Metastatic Breast Cancer
What this study did
NCT01626222 · Novartis Pharmaceuticals
2012-06 – 2013-11 · Metastatic Breast Cancer
What this study did
Renal Cell Carcinoma
NCT07165418 · Peking University Cancer Hospital & Institute
2025-09-25 – 2029-12-30 · Renal Cell Carcinoma (RCC)
What this study did
NCT02811861 · Eisai Inc.
2016-10-13 – 2027-03-31 · Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT07739914 · Hannover Medical School
2026-08-19 – 2031-06-30 · Liver Allograft, Liver Diseases, Liver Transplantation
What this study did
NCT01120249 · SWOG Cancer Research Network
2011-04-01 – 2025-09-01 · Kidney Cancer
What this study did
NCT01595984 · Centre Hospitalier Universitaire, Amiens
2012-05-03 – 2024-03-05 · Kidney Failure
What this study did
NCT03580239 · Tianjin Medical University Second Hospital
2019-01-01 – 2023-12-01 · Prostate Cancer
What this study did
NCT03386539 · Boston Children's Hospital
2018-01-29 – 2023-05-17 · Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy, Heart Transplant Failure and Rejection, Post-transplant Lymphoproliferative Disorder, Heart Transplant Infection
What this study did
NCT02246127 · Grupo Espanol de Tumores Neuroendocrinos
2014-10-27 – 2021-07-12 · Neuroendocrine Tumors
What this study did
NCT01524783 · Novartis Pharmaceuticals
2012-03-30 – 2020-08-07 · Advanced NET of GI Origin, Advanced NET of Lung Origin, Neuroendocrine Tumors
What this study did
NCT02334488 · Poitiers University Hospital
2014-12-11 – 2020-07-03 · Chronic Kidney Disease
What this study did
NCT04063865 · Indiana University
2019-05-09 – 2020-07-02 · Kidney Failure
What this study did
NCT04258423 · Indiana University
2019-12-19 – 2020-06-27 · Kidney Failure
What this study did
NCT01248403 · Krankenhaus Nordwest
2011-10 – 2019-10 · Advanced Gastric Cancer, Esophagogastric Junction Cancer
What this study did
NCT01544491 · Novartis Pharmaceuticals
2012-08-17 – 2018-09-24 · Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
What this study did
NCT01888432 · Novartis Pharmaceuticals
2013-09-25 – 2018-04-21 · Liver Transplantation
What this study did
NCT02134899 · Assistance Publique - Hôpitaux de Paris
2014-10-14 – 2017-11-11 · Autosomal Dominant Polycystic Kidney Disease
What this study did
NCT01404325 · Novartis Pharmaceuticals
2012-02-01 – 2017-01-05 · Lung Transplantation
What this study did
NCT02115113 · Novartis Pharmaceuticals
2014-03-28 – 2016-09-30 · Liver Transplantation
What this study did
NCT01707849 · Hospital Vall d'Hebron
2012-10 – 2016-08 · Hepatitis C Recurrence After Liver Transplant
What this study did
NCT01598987 · Novartis Pharmaceuticals
2012-10 – 2016-06 · Renal Function, Liver Transplant
What this study did
NCT01843348 · Novartis Pharmaceuticals
2012-12-27 – 2016-03-23 · Kidney Transplantation, Renal Transplantation
What this study did
NCT01410448 · Novartis Pharmaceuticals
2011-11 – 2015-12 · Kidney Transplantation
What this study did
NCT00790400 · Novartis Pharmaceuticals
2009-04 – 2015-11 · Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
What this study did
NCT02314312 · Mahidol University
2012-01 – 2015-06 · Transplantation of Kidney, Expanded Criteria Donor, ECD
What this study did
NCT00514514 · Novartis Pharmaceuticals
2007-07 – 2015-06 · Kidney Transplantation
What this study did
Phase 2/3 (10)
Other / comorbidity
NCT07218575 · Boston Children's Hospital
2026-09-01 – 2030-09 · Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease, Cerebellum Dysplastic Gangliocytoma, Bannayan Zonana Syndrome, Myhre Riley Smith Syndrome, Riley Smith Syndrome, PTEN Hamartoma Tumor Syndrome, Bannayan Riley Ruvalcaba Syndrome
What this study did
NCT03458221 · Gynaecologisch Oncologisch Centrum Zuid
2023-01-31 – 2026-10-01 · Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation, Therapy-Associated Cancer
What this study did
NCT05833815 · Banaras Hindu University
2022-11-01 – 2024-12-30 · Gallbladder Cancer
What this study did
NCT02860494 · Hospices Civils de Lyon
2020-12 – 2024-12 · Facial Angiofibromas
What this study did
NCT03285802 · Greater Baltimore Medical Center
2017-09-07 – 2019-02-12 · Uterine Cancer
What this study did
NCT01878786 · Matthew Cooper
2013-06 – 2017-12 · Delayed Graft Function
What this study did
NCT01730209 · Erasmus Medical Center
2012-11 – 2016-11 · Tuberous Sclerosis Complex, TSC Related Cognitive Disability, TSC Related Autism, TSC Related Learning Problems
What this study did
NCT01009957 · A. Manzoni Hospital
2008-06 – 2015-06 · Polycystic Kidney Diseases
What this study did
NCT01023542 · University of Regensburg
2011-06 – 2014-12 · Renal Impairment, Liver Transplantation, Everolimus
What this study did
NCT00117702 · Technische Universität Dresden
2005-10 – 2008-05 · Graft vs Host Disease
What this study did
Phase 2 (294)
Breast Cancer
NCT07340541 · UNC Lineberger Comprehensive Cancer Center
2026-02-16 – 2031-06-02 · Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
What this study did
NCT05749588 · Fudan University
2023-03-30 – 2028-12-31 · Triple-negative Breast Cancer
What this study did
NCT07900516 · The First Affiliated Hospital with Nanjing Medical University
2026-08-01 – 2028-08-01 · Breast Cancer
What this study did
NCT03032406 · Abramson Cancer Center at Penn Medicine
2017-01-23 – 2027-01-01 · Breast Cancer Stage IIB
What this study did
NCT04395989 · Fudan University
2020-07-28 – 2024-12-31 · TNBC - Triple-Negative Breast Cancer
What this study did
NCT02742051 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2016-06 – 2020-03-14 · Breast Cancer
What this study did
NCT01305941 · UNC Lineberger Comprehensive Cancer Center
2011-09 – 2017-10-16 · HER-2 Positive Breast Cancer
What this study did
NCT01283789 · University of Kansas Medical Center
2011-02 – 2017-04 · Metastatic Breast Cancer
What this study did
NCT00930930 · Vanderbilt-Ingram Cancer Center
2009-06 – 2014-10 · Breast Cancer
What this study did
NCT01272141 · Emory University
2010-12 – 2014-01 · Breast Neoplasms, Breast Cancer, Cancer of the Breast
What this study did
NCT01163929 · University of Kansas
2010-07 – 2012-03 · Breast Cancer
What this study did
NCT00827567 · Milton S. Hershey Medical Center
2009-04 – 2011-02 · Breast Cancer
What this study did
Epilepsy
NCT05613166 · National Institute on Drug Dependence, China
2022-11 – 2023-03 · Epilepsy
What this study did
NCT03198949 · Yonsei University
2018-05-24 – 2020-09-11 · Epilepsy and Focal Cortical Dysplasia II
What this study did
NCT02451696 · NYU Langone Health
2014-01 – 2017-12-28 · Epilepsy, Tuberous Sclerosis Complex, Focal Cortical Dysplasia
What this study did
NCT01997255 · Baylor College of Medicine
2014-04 – 2016-04 · Sturge Weber Syndrome
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05933395 · Dartmouth-Hitchcock Medical Center
2024-09-23 – 2031-10 · Advanced Breast Cancer
What this study did
NCT07937605 · Beijing Konruns Pharmaceutical Co., Ltd.
2026-11 – 2030-11 · HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
What this study did
NCT07634601 · Jonsson Comprehensive Cancer Center
2026-12-18 – 2029-12-18 · Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Endometrial Cancer, Stage IV Endometrial Cancer
What this study did
NCT05949541 · Fudan University
2023-07-26 – 2028-01 · Breast Cancer, Advanced Breast Cancer
What this study did
NCT05983107 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2023-07-20 – 2027-07-15 · HR+/HER2- Advanced Breast Cancer, Targeted Therapy
What this study did
NCT05594095 · Fudan University
2022-12-30 – 2026-12-01 · Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
NCT06561022 · Fudan University
2024-08-21 – 2026-06-30 · Breast Cancer
What this study did
NCT04591431 · Fondazione per la Medicina Personalizzata
2020-10-07 – 2025-06 · Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
What this study did
NCT04355858 · Fudan University
2020-05-01 – 2025-04-01 · Breast Cancer, Metastatic Cancer
What this study did
NCT02028364 · Jules Bordet Institute
2014-01-12 – 2021-08-09 · Breast Cancer
What this study did
NCT02387099 · GBG Forschungs GmbH
2015-05 – 2021-07 · Breast Cancer, Hormone Receptor Positive Tumor
What this study did
NCT02236572 · Yale University
2014-11-29 – 2021-03-01 · Breast Cancer
What this study did
NCT02269670 · Emory University
2014-11-25 – 2021-01-25 · Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT01698918 · Novartis Pharmaceuticals
2013-03-07 – 2021-01-13 · Hormone Receptor Positive Breast Cancer
What this study did
NCT01627067 · M.D. Anderson Cancer Center
2012-09 – 2019-02-01 · Breast Cancer
What this study did
NCT02291913 · SCRI Development Innovations, LLC
2014-12-18 – 2019-01-31 · Breast Cancer
What this study did
NCT01931163 · Jenny C. Chang, MD
2013-07 – 2019-01 · Breast Cancer, Triple Negative Breast Cancer
What this study did
NCT02015559 · Jonsson Comprehensive Cancer Center
2014-10-08 – 2018-11-30 · Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Oral Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT02344550 · Asan Medical Center
2014-01 – 2018-10 · Metastatic Breast Cancer
What this study did
NCT01298713 · ARCAGY/ GINECO GROUP
2008-03 – 2018-09-12 · Breast Neoplasms, mTor Protein
What this study did
NCT01783444 · Novartis Pharmaceuticals
2013-02-26 – 2018-07-30 · Breast Cancer
What this study did
NCT02283658 · Mayo Clinic
2014-11-14 – 2018-06-21 · Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma
What this study did
NCT02313051 · Chinese Academy of Medical Sciences
2014-12 – 2017-12 · Metastatic Breast Cancer
What this study did
NCT01797120 · PrECOG, LLC.
2013-05-31 – 2017-09-12 · Metastatic Breast Cancer
What this study did
NCT00912340 · Emory University
2009-05 – 2017-07 · Breast Cancer
What this study did
NCT01231659 · Novartis Pharmaceuticals
2011-08-09 – 2017-04-30 · Postmenopausal Women, Locally Advanced Metastatic Breast Cancer, Metastatic Breast Cancer
What this study did
NCT00499603 · M.D. Anderson Cancer Center
2007-07 – 2017-04 · Breast Cancer
What this study did
NCT01499160 · University of Maryland, Baltimore
2012-05 – 2016-12 · Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis
What this study did
NCT01520103 · AIO-Studien-gGmbH
2012-01 – 2016-10-31 · Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer
What this study did
NCT02025712 · Organisation for Oncology and Translational Research
est. completion 2016-08 · Hormone Receptor Positive Malignant Neoplasm of Breast
What this study did
Phase 1/2 (100)
Breast Cancer
NCT03805399 · Fudan University
2018-10-18 – 2022-12-01 · Triple-negative Breast Cancer
What this study did
NCT01939418 · National Cancer Center, Korea
2013-08 – 2017-07-30 · Metastatic Breast Cancer
What this study did
NCT00458237 · Beth Israel Deaconess Medical Center
2007-04 – 2010-04 · Breast Cancer
What this study did
Epilepsy
NCT01070316 · Children's Hospital Medical Center, Cincinnati
2010-01 – 2016-04 · Epilepsy, Tuberous Sclerosis Complex
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT04802759 · Hoffmann-La Roche
2021-06-22 – 2029-05-30 · Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
What this study did
NCT05563220 · Stemline Therapeutics, Inc.
2023-01-24 – 2028-12-28 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT07002177 · Forward Pharmaceuticals Co., Ltd.
2025-06-01 – 2028-11-01 · Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Locally Advanced Breast Cancer (LABC), ER+ Breast Cancer
What this study did
NCT05573126 · Ellipses Pharma
2023-01-11 – 2028-02 · Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
What this study did
NCT02520063 · University of Alabama at Birmingham
2015-02-01 – 2022-12-01 · Breast Cancer
What this study did
NCT02871791 · Dana-Farber Cancer Institute
2016-08-24 – 2021-09 · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer
What this study did
NCT02732119 · Novartis Pharmaceuticals
2016-06-14 – 2020-02-25 · Breast Cancer
What this study did
NCT01783756 · Jonsson Comprehensive Cancer Center
2013-06-26 – 2019-05-10 · Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT01031446 · Vanderbilt-Ingram Cancer Center
2009-10 – 2017-08 · Breast Cancer
What this study did
NCT00934895 · Rutgers, The State University of New Jersey
2009-07-15 – 2015-08-12 · Breast Cancer
What this study did
NCT00317720 · M.D. Anderson Cancer Center
2006-04 – 2013-02 · Breast Cancer, Neoplasm Metastasis
What this study did
NCT00930475 · Charite University, Berlin, Germany
2009-02 – 2010-12 · Breast Cancer
What this study did
Renal Cell Carcinoma
NCT02599324 · Pharmacyclics LLC.
2015-12-01 – 2021-08-20 · Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
What this study did
NCT01510119 · Abramson Cancer Center at Penn Medicine
2011-09 – 2017-01-05 · Metastatic Clear Cell Renal Cell Carcinoma
What this study did
NCT01034631 · Hoosier Cancer Research Network
2010-01 – 2016-12 · Renal Cell Carcinoma
What this study did
NCT01582009 · Roswell Park Cancer Institute
2010-03 – 2015-12 · Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
What this study did
Other / comorbidity
NCT02813135 · Gustave Roussy, Cancer Campus, Grand Paris
2016-08-03 – 2031-02 · Pediatric Cancer
What this study did
NCT07435584 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-03-01 – 2028-12-31 · Colorectal Cancer
What this study did
NCT06682611 · Shanghai Runshi Pharmaceutical Technology Co., Ltd
2024-11-13 – 2027-11-13 · Unresectable Locally Advanced or Metastatic Solid Tumors
What this study did
NCT06727305 · University of Texas Southwestern Medical Center
2026-05-11 – 2027-11-13 · Aging
What this study did
NCT03697408 · University of Pennsylvania
2019-02-11 – 2027-06 · Classical Hodgkin Lymphoma
What this study did
NCT02579044 · Boston Children's Hospital
2015-12 – 2027-03 · Progeria
What this study did
NCT03577431 · National Institute of Allergy and Infectious Diseases (NIAID)
2019-03-29 – 2026-02-05 · Liver Transplant
What this study did
NCT04339062 · Dana-Farber Cancer Institute
2020-11-03 – 2025-03-01 · Cutaneous Squamous Cell Carcinoma, Advanced Cancer
What this study did
NCT04066114 · National Institute of Allergy and Infectious Diseases (NIAID)
2019-12-11 – 2023-09-14 · Living-Donor Kidney Transplant, Kidney Transplant Recipients
What this study did
NCT02711826 · National Institute of Allergy and Infectious Diseases (NIAID)
2016-09-20 – 2023-08-04 · Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant, Living Kidney Donor
What this study did
NCT03654040 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-04-22 – 2023-03-06 · Liver Transplant
What this study did
NCT03245151 · Eisai Inc.
2017-11-16 – 2022-09-30 · Recurrent and Refractory Solid Tumors
What this study did
NCT01062399 · Radiation Therapy Oncology Group
2010-12 – 2022-05-20 · Brain and Central Nervous System Tumors
What this study did
NCT02991807 · Boston Children's Hospital
2017-06-12 – 2021-12-22 · PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome
What this study did
NCT01529554 · University of Zurich
2015-01-08 – 2021-11-29 · Acute Coronary Syndromes
What this study did
NCT02205515 · Sunnybrook Health Sciences Centre
2016-03 – 2021-10 · Carcinoma, Neuroendocrine
What this study did
NCT01434602 · National Cancer Institute (NCI)
2012-10-02 – 2021-07-13 · Brain Tumor, Glioblastoma, Anaplastic Glioma
What this study did
NCT02985125 · Georgetown University
2017-05-04 – 2020-09-28 · Metastatic Pancreatic Adenocarcinoma
What this study did
NCT01784861 · Washington University School of Medicine
2013-05-03 – 2020-08-19 · Adenocarcinoma, Pancreatic Neoplasms
What this study did
NCT01075321 · Mayo Clinic
2011-01-10 – 2020-02-13 · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT02061397 · University of Pennsylvania
2014-03 – 2019-12-13 · Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
What this study did
NCT00553150 · Alliance for Clinical Trials in Oncology
2009-03 – 2019-11-15 · Brain and Central Nervous System Tumors
What this study did
NCT00474929 · Mayo Clinic
2007-08-29 – 2019-08-08 · Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00918333 · Mayo Clinic
2009-06 – 2019-07-16 · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, Waldenström Macroglobulinemia
What this study did
NCT00576680 · Dana-Farber Cancer Institute
2008-05 – 2019-03-29 · Pancreatic Neuroendocrine Tumor
What this study did
NCT01514110 · Chinese University of Hong Kong
2008-01-23 – 2019-03-06 · Gastric Cancer
What this study did
NCT01453504 · University of Cologne
2012-08 – 2019-03 · Hodgkin Lymphoma
What this study did
NCT03629847 · King Faisal Specialist Hospital & Research Center
2012-12 – 2018-12 · Neuroendocrine Tumors
What this study did
Phase 1 (162)
Breast Cancer
NCT02120469 · City of Hope Medical Center
2014-11-17 – 2020-03-03 · Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor-negative, Stage IV Breast Cancer, Triple-negative Breast Carcinoma
What this study did
NCT02616848 · Istituti Ospitalieri di Cremona
2015-11 – 2015-11 · Triple Negative Breast Cancer
What this study did
NCT00426556 · Novartis Pharmaceuticals
2007-07 – 2014-03 · Metastatic Breast Cancer
What this study did
NCT00426530 · Novartis Pharmaceuticals
2007-02 – 2010-06 · Breast Neoplasms, Neoplasm Metastasis
What this study did
Epilepsy
NCT07095933 · Xuanwu Hospital, Beijing
2026-07-01 – 2026-12-31 · Epilepsy, Drug Resistant
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05508906 · Olema Pharmaceuticals, Inc.
2022-08-31 – 2028-01-31 · Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT04188548 · Eli Lilly and Company
2019-12-10 – 2027-12 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
What this study did
NCT03616587 · AstraZeneca
2018-10-11 – 2027-06-24 · ER+ HER2- Advanced Breast Cancer
What this study did
NCT02057133 · Eli Lilly and Company
2014-03-10 – 2026-12 · Breast Neoplasms
What this study did
NCT05293964 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2022-05-18 – 2025-09-08 · Breast Cancer
What this study did
NCT05501769 · Arvinas Estrogen Receptor, Inc.
2022-09-08 – 2025-08-25 · Breast Cancer
What this study did
NCT05189717 · Shandong Suncadia Medicine Co., Ltd.
2022-02-17 – 2025-07-31 · Metastatic or Local Advanced Breast Cancer of Patients
What this study did
NCT04818632 · AstraZeneca
2021-11-12 – 2023-09-07 · ER+, HER2-, Metastatic Breast Cancer
What this study did
NCT03154281 · Avera McKennan Hospital & University Health Center
2017-07-26 – 2023-05-01 · Breast Cancer, Ovarian Cancer
What this study did
NCT02123823 · Boehringer Ingelheim
2014-05-15 – 2021-12-14 · Neoplasms
What this study did
NCT02152943 · M.D. Anderson Cancer Center
2014-07-17 – 2020-12-14 · Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal, Premenopausal, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Refractory Hormone Receptor Positive Breast Carcinoma, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT01857193 · Novartis Pharmaceuticals
2013-09-06 – 2020-04-16 · Breast Cancer
What this study did
NCT02077933 · Novartis Pharmaceuticals
2014-05-14 – 2019-04-12 · Neoplasms, Breast Neoplasms, Kidney Neoplasms, Pancreatic Neuroendocine Neoplasms (pNETs)
What this study did
NCT01482156 · Novartis Pharmaceuticals
2012-01 – 2015-02 · Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma
What this study did
NCT00253318 · M.D. Anderson Cancer Center
2005-11-01 – 2012-04 · Breast Cancer
What this study did
NCT00473005 · Stanford University
2007-08 – 2011-12 · Breast Cancer
What this study did
NCT00680758 · Vanderbilt-Ingram Cancer Center
2008-05 – 2010-12 · Breast Cancer
What this study did
NCT00574366 · Vanderbilt-Ingram Cancer Center
2005-12 – 2009-02 · Breast Cancer
What this study did
Renal Cell Carcinoma
NCT05188118 · Icahn School of Medicine at Mount Sinai
2023-02-15 – 2025-04-30 · Renal Cell Carcinoma
What this study did
NCT03324373 · Yousef Zakharia
2019-03-20 – 2024-08-28 · Renal Cell Carcinoma
What this study did
NCT02890069 · Novartis Pharmaceuticals
2016-10-14 – 2022-02-22 · Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
What this study did
NCT02577458 · AnewPharma
2015-09 – 2018-06 · Renal Cell Carcinoma Recurrent
What this study did
NCT02454478 · Eisai Co., Ltd.
2015-07-01 – 2017-05-29 · Carcinoma, Renal Cell
What this study did
NCT00384969 · University of California, San Francisco
2006-10 – 2014-03 · Renal Cell Carcinoma
What this study did
NCT01677390 · Seagen Inc.
2012-08 – 2013-12 · Renal Cell Carcinoma
What this study did
NCT01152801 · Novartis Pharmaceuticals
2010-05 – 2013-12 · Metastatic Renal Cell Carcinoma
What this study did
NCT00788060 · Daniel George, MD
2008-10 – 2012-12 · Renal Cell Carcinoma
What this study did
NCT01115803 · Eli Lilly and Company
2010-03 – 2011-06 · Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
What this study did
NCT00422344 · Memorial Sloan Kettering Cancer Center
2006-10 – 2010-02 · Renal Cell Carcinoma, Kidney Cancer
What this study did
Other / comorbidity
NCT07865130 · Bożenna Dembowska Bagińska
2026-09 – 2033-06 · Medulloblastoma Recurrent, Medulloblastoma
What this study did
NCT07318324 · M.D. Anderson Cancer Center
2026-05-13 – 2030-08-01 · Phase IB, Avutometinib, RAS Pathway, Endometrial
What this study did
NCT06832189 · National Institute of Allergy and Infectious Diseases (NIAID)
2026-01-21 – 2030-06-01 · Liver Transplant
What this study did
NCT06994572 · Captor Therapeutics S.A.
2025-05-26 – 2030-04-01 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05949658 · University of Wisconsin, Madison
2024-05-15 – 2028-12 · Aging
What this study did
NCT06658093 · The University of Texas Health Science Center at San Antonio
2026-03-04 – 2028-07 · Aging
What this study did
NCT04485559 · University of California, San Francisco
2020-12-09 – 2027-12-31 · Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High-Grade Glioma (HGG)
What this study did
NCT04185883 · Amgen
2019-12-17 – 2027-12-05 · Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
What this study did
NCT05432518 · AHS Cancer Control Alberta
2023-06-27 – 2027-12-01 · Glioblastoma, Recurrent Disease, Recurrent Glioblastoma
What this study did
NCT03740334 · Dana-Farber Cancer Institute
2019-01-30 – 2027-04-30 · Acute Lymphoblastic Leukemia ALL
What this study did
NCT02321501 · M.D. Anderson Cancer Center
2016-06-22 – 2026-12-31 · ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT00819546 · Richard Stone, MD
2009-01 – 2026-12 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT01087554 · M.D. Anderson Cancer Center
2010-03 – 2026-08-18 · Advanced Cancer
What this study did
NCT03065387 · M.D. Anderson Cancer Center
2017-10-31 – 2026-04-23 · Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification, ERBB2 Gene Mutation, ERBB3 Gene Mutation, ERBB4 Gene Mutation, KRAS Gene Mutation, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
What this study did
Phase 4 (97)
HR+/HER2- Metastatic Breast Cancer
NCT01948960 · Radboud University Medical Center
2013-08 – 2018-01-15 · Breast Neoplasms
What this study did
NCT02248571 · iOMEDICO AG
2014-08 – 2017-09-30 · Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast
What this study did
NCT01743560 · Novartis Pharmaceuticals
2013-01-31 – 2016-08-15 · Oestrogen Receptor Positive Advanced Breast Cancer
What this study did
Renal Cell Carcinoma
NCT02338570 · Mario Negri Institute for Pharmacological Research
2015-07 – 2018-02 · Renal Cell Carcinoma
What this study did
NCT01266837 · iOMEDICO AG
2011-03 – 2017-10-31 · Metastatic Renal Cell Carcinoma, Failure of Exactly One Prior VEGF-targeted Therapy
What this study did
NCT01206764 · Novartis Pharmaceuticals
2009-11-11 – 2017-07-01 · Renal Cell Carcinoma
What this study did
NCT01514448 · Novartis Pharmaceuticals
2012-05-21 – 2016-04-01 · Metastatic Renal Cell Carcinoma (mRCC)
What this study did
NCT02056587 · Kidney Cancer Research Bureau
2011-11 – 2013-10 · Metastatic Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT07426484 · Dana-Farber Cancer Institute
2026-04-23 – 2032-12-15 · Cutaneous Squamous Cell Carcinoma, Skin Cancer
What this study did
NCT06942156 · Chong Kun Dang Pharmaceutical
2025-08-14 – 2030-12 · Heart Transplant
What this study did
NCT07570433 · Oriol Manuel
2026-04 – 2028-03 · CMV Infection
What this study did
NCT02081755 · Baylor Research Institute
2014-03 – 2027-03 · Carcinoma, Hepatocellular
What this study did
NCT03797196 · University Medical Center Groningen
2019-07-29 – 2026-12 · Renal Transplant Recipients, Elderly Patients, Immunosuppression
What this study did
NCT05252585 · Novartis Pharmaceuticals
2023-05-01 – 2026-10-13 · Renal Angiomyolipoma
What this study did
NCT06584773 · University of Sao Paulo General Hospital
2015-06 – 2025-07 · Disorder Related to Renal Transplantation
What this study did
NCT03216967 · University Hospital, Strasbourg, France
2018-01-15 – 2024-08-01 · BK Virus Nephropathy After Kidney Transplantation
What this study did
NCT04471441 · Chong Kun Dang Pharmaceutical
2020-06-30 – 2024-07-24 · Liver Transplant
What this study did
NCT04849533 · University of Cincinnati
2021-04-09 – 2024-07 · Kidney Transplant Rejection
What this study did
NCT02842749 · Novartis Pharmaceuticals
2016-03-14 – 2024-02-22 · Pancreatic Neuroendocrine Tumors
What this study did
NCT02338609 · Novartis Pharmaceuticals
2014-12-17 – 2023-12-18 · Growth and Development
What this study did
NCT04867720 · Chong Kun Dang Pharmaceutical
2021-03-16 – 2023-02-22 · Liver Transplant
What this study did
NCT02254668 · University of Zurich
2013-12 – 2023-02 · Intimal Proliferation, Immunosuppression
What this study did
NCT03468478 · Hospital do Rim e Hipertensão
2017-06-18 – 2021-08-23 · Kidney Transplant Infection
What this study did
NCT03525834 · Novartis Pharmaceuticals
2018-11-09 – 2020-09-25 · Renal Angiomyolipoma
What this study did
NCT01789281 · Novartis Pharmaceuticals
2013-05-14 – 2020-08-28 · Neoplasms
What this study did
NCT01935128 · University of Toledo Health Science Campus
2013-07-03 – 2020-07 · Renal Transplant
What this study did
NCT03256864 · Chang Gung Memorial Hospital
2016-01 – 2020-05-30 · Liver Transplantation
What this study did
NCT03415750 · Edoardo Melilli
2016-11 – 2020-05 · Hypertrophy, Left Ventricular
What this study did
NCT02049229 · The Hospital District of Satakunta
2014-01 – 2019-10 · Myocardial Infarction, Percutaneous Coronary Intervention, Atherosclerosis
What this study did
NCT02974686 · Washington University School of Medicine
2016-11 – 2019-09 · Kidney Transplant Rejection, Gastrointestinal Disorder, Functional
What this study did
NCT01631058 · University of Sao Paulo General Hospital
2012-07 – 2019-06 · Chronic Renal Failure (CRF), Graft Failure, Transplant; Failure, Kidney, Renal Transplant Rejection
What this study did
NCT02077556 · National Taiwan University Hospital
2014-04 – 2019-01-15 · Drug Interaction Potentiation
What this study did
NCT01289301 · Hannover Medical School
2011-10 – 2018-10 · Disorder Related to Renal Transplantation, Immunosuppression Related Infectious Disease, Virus Diseases
What this study did
NCT02429869 · University of California, San Francisco
2016-02-24 – 2018-01-31 · HIV, Kidney Transplant, Liver Transplant
What this study did
NCT01950819 · Novartis Pharmaceuticals
2013-12-03 – 2018-01-17 · End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy, Renal Transplantation
What this study did
NCT02864706 · Novartis Pharmaceuticals
2016-01-18 – 2017-09-25 · Heart Transplantation
What this study did
NCT01551212 · Novartis Pharmaceuticals
2012-05-24 – 2017-08-08 · Liver Transplantation
What this study did
NCT02493465 · Instituto de Urologia e Nefrologia
2015-07 – 2017-07 · Left Ventricular Hypertrophy
What this study did
NCT02084446 · Ronaldo de Matos Esmeraldo, MD
2012-12 – 2017-07 · Transplantation Infection, Cytomegalovirus Infections
What this study did
NCT02096107 · Medical University of South Carolina
2014-02 – 2017-05 · Graft Dysfunction, Interstitial Fibrosis
What this study did
NCT01895049 · Helio Tedesco Silva Junior
2013-08 – 2017-03-07 · Kidney Transplantation, Cytomegalovirus
What this study did
NCT00862979 · Novartis Pharmaceuticals
2009-02-24 – 2017-03-06 · Heart Transplantation
What this study did
NCT02036554 · Seoul St. Mary's Hospital
2013-03 – 2015-12 · Kidney; Complications, Allograft
What this study did
NCT01927588 · Fundação Pró Rim
2013-08 – 2015-11 · Cytomegalovirus Infections
What this study did
NCT01624948 · University of California, San Francisco
2012-09 – 2015-11 · BK Virus Infection
What this study did
NCT00997763 · Seung-Jung Park
2008-07 – 2015-08 · Coronary Artery Disease
What this study did
NCT01663805 · MARIO ABBUD FILHO
2012-01 – 2015-06 · Delayed Function of Renal Transplant
What this study did
NCT01239472 · Andre Barreto Pereira
2011-01 – 2015-06 · Renal Transplant Rejection, Immunosuppression
What this study did
Early phase / not applicable (34)
HR+/HER2- Metastatic Breast Cancer
NCT02854618 · Centre Hospitalier Universitaire de Besancon
2015-11-26 – 2022-05 · Breast Cancer
What this study did
NCT02109913 · Amsterdam UMC, location VUmc
2014-03 – 2021-01 · Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer
What this study did
Renal Cell Carcinoma
NCT06317298 · Peking University First Hospital
2024-02-21 – 2025-12-01 · Renal Cell Carcinoma, Clear Cell, Somatic
What this study did
NCT02208128 · Heidelberg University
2014-05 – 2018-02 · Renal Cell Carcinoma
What this study did
NCT01107509 · St. Joseph's Healthcare Hamilton
2010-10-01 – 2017-10-01 · Carcinoma, Renal Cell
What this study did
NCT01598038 · Centre Francois Baclesse
2012-04 – 2015-12 · Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT04199026 · M.D. Anderson Cancer Center
2025-02-25 – 2028-12-31 · Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
What this study did
NCT04542733 · King Chulalongkorn Memorial Hospital
2023-06-15 – 2028-07 · Kidney Transplant Infection, BK Virus Infection
What this study did
NCT03955172 · Hospices Civils de Lyon
2020-12-03 – 2027-12-03 · Kidney Transplant Failure and Rejection
What this study did
NCT02736227 · Northwestern University
2016-03 – 2021-03 · Liver Transplantation
What this study did
NCT01858077 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2013-08 – 2020-12 · Coronary Artery Disease, Myocardial Infarction
What this study did
NCT04906304 · Shahid Beheshti University of Medical Sciences
2020-01-01 – 2020-08-01 · Cytomegalovirus Infections
What this study did
NCT01653847 · Northwestern University
2013-02 – 2020-05 · End Stage Renal Failure With Renal Transplant
What this study did
NCT02837757 · Centre Hospitalier Universitaire de Besancon
2015-11 – 2019-12-18 · Metastatic Renal Cancer
What this study did
NCT01636908 · Amsterdam UMC, location VUmc
2011-08 – 2019-12-01 · Cancer, Advanced Solid Tumors
What this study did
NCT02229864 · Abbott Medical Devices
2014-05 – 2019-10-01 · Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
What this study did
NCT01976390 · Ohio State University
2013-10-01 – 2019-08-31 · Renal Failure
What this study did
NCT01936519 · Milton S. Hershey Medical Center
2013-12-16 – 2019-07-31 · Immunosuppression, Renal Failure
What this study did
NCT03401216 · Meshalkin Research Institute of Pathology of Circulation
2017-03-20 – 2019-04-30 · Ischemic Heart Disease, Coronary Artery Disease, Coronary Atherosclerosis
What this study did
NCT03403647 · Sheba Medical Center
2018-07-15 – 2019-04-10 · Vitamin D Deficiency
What this study did
NCT02954198 · Medical University of South Carolina
2016-12-01 – 2018-12-27 · Immunosuppression
What this study did
NCT02013089 · Sun Yat-sen University
2013-12 – 2017-12 · Gastrointestinal Cancers
What this study did
NCT02015728 · Seattle Children's Hospital
2013-12 – 2017-12 · Recurrent Childhood Brain Tumor
What this study did
NCT01566279 · UMC Utrecht
2012-08 – 2016-11 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT02091973 · Chulalongkorn University
2010-06 – 2015-12 · microRNA Profiles
What this study did
NCT01807767 · Medical College of Wisconsin
2013-03 – 2015-08 · High Model for End-Stage Liver Disease (MELD) Score
What this study did
NCT01640743 · Fondazione IRCCS Policlinico San Matteo di Pavia
2010-03 – 2014-04 · Kidney Transplantation
What this study did
NCT01609673 · Helady Pinheiro, MD, PhD
2013-03 – 2013-05 · End Stage Renal Failure With Renal Transplant
What this study did
NCT01780948 · Chulalongkorn University
2012-09 – 2013-01 · Difference of 12-hour AUC
What this study did
NCT01473732 · Montefiore Medical Center
2012-03 – 2012-08 · Chronic Allograft Injury, Calcineurin Inhibitor Toxicity
What this study did
Used as active comparator (35)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (16)
HR+/HER2- Metastatic Breast Cancer
NCT07024173 · Shandong Suncadia Medicine Co., Ltd.
2025-07-23 – 2027-12 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT05065411 · Veru Inc.
2022-04-11 – 2024-01-09 · Metastatic Breast Cancer
What this study did
Renal Cell Carcinoma
NCT04195750 · Merck Sharp & Dohme LLC
2020-02-27 – 2026-10-14 · Carcinoma, Renal Cell
What this study did
NCT03095040 · AnewPharma
2016-12-16 – 2021-12 · Renal Cell Cancer Metastatic
What this study did
NCT01668784 · Bristol-Myers Squibb
2012-10-09 – 2021-07-19 · Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
What this study did
NCT01865747 · Exelixis
2013-06 – 2021-01-15 · Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT05476939 · Gustave Roussy, Cancer Campus, Grand Paris
2022-09-29 – 2031-09 · Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered
What this study did
NCT05477576 · RayzeBio, Inc.
2022-03-24 – 2030-12 · GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
What this study did
NCT03049189 · ITM Solucin GmbH
2017-02-02 – 2029-11 · Neuroendocrine Tumors
What this study did
NCT05918302 · Grupo Espanol de Tumores Neuroendocrinos
2023-10-27 – 2029-10 · Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms
What this study did
NCT04919226 · ITM Solucin GmbH
2021-12-21 – 2027-09 · Neuroendocrine Tumors
What this study did
NCT03112603 · Incyte Corporation
2017-06-29 – 2022-12-15 · Graft-versus-host Disease (GVHD)
What this study did
NCT03596970 · Novartis Pharmaceuticals
2015-09 – 2020-12 · Liver Transplantation
What this study did
NCT00378014 · Novartis Pharmaceuticals
2006-08 – 2013-01 · Liver Transplantation
What this study did
NCT00267189 · Novartis Pharmaceuticals
2005-11 – 2007-11 · Liver Transplantation
What this study did
Phase 2/3 (3)
Renal Cell Carcinoma
NCT05522231 · Hutchmed
2022-10-27 – 2026-08-28 · Advanced Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT06943755 · Exelixis
2025-07-21 – 2029-06-30 · Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
What this study did
NCT07165886 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2025-08-29 – 2028-08-29 · Gastroenteropancreatic Neuroendocrine Tumors
What this study did
Phase 2 (10)
HR+/HER2- Metastatic Breast Cancer
NCT06428396 · Merck Sharp & Dohme LLC
2024-11-27 – 2028-12-25 · Metastatic Breast Cancer
What this study did
NCT05079360 · Veru Inc.
2023-03-15 – 2024-05-26 · Metastatic Breast Cancer
What this study did
NCT02216786 · Queen Mary University of London
2014-01-16 – 2021-12-31 · Estrogen Receptor Positive Breast Cancer
What this study did
Renal Cell Carcinoma
NCT02724020 · Millennium Pharmaceuticals, Inc.
2016-06-30 – 2020-10-13 · Clear-cell Metastatic Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT04665739 · National Cancer Institute (NCI)
2023-02-03 – 2032-09-01 · Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor G1, Lung Neuroendocrine Tumor G2, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Non-Functioning Lung Neuroendocrine Tumor, Recurrent Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Tumor
What this study did
NCT05773274 · National Cancer Institute (NCI)
2024-01-12 – 2029-04-30 · Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
What this study did
NCT05132166 · University Health Network, Toronto
2021-12-22 – 2026-04-26 · Graft Vs Host Disease
What this study did
NCT01628913 · Novartis Pharmaceuticals
2012-10 – 2014-09 · Pancreatic Neuroendocrine Tumors (pNET)
What this study did
Phase 4 (2)
Other / comorbidity
NCT04936971 · Edoardo Melilli
2021-09 – 2021-09 · Kidney Transplantation, Cytomegalovirus Infections
What this study did
NCT00888758 · Masaryk University
2009-05 – 2011-05 · Coronary Heart Disease, Percutaneous Coronary Intervention
What this study did
Early phase / not applicable (4)
Other / comorbidity
NCT05540223 · Biotronik AG
2024-05-13 – 2032-02 · Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease, Acute Coronary Syndrome, Angina Pectoris
What this study did
NCT05516446 · General Administration of Military Health, Tunisia
2021-08-25 – 2022-12 · Percutaneous Coronary Intervention (PCI), Coronary Artery Disease (CAD), De Novo Stenosis
What this study did
NCT02389946 · Biotronik, Inc.
2015-05 – 2021-03 · Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease, Acute Coronary Syndrome, Angina Pectoris
What this study did
NCT02305485 · Lepu Medical Technology (Beijing) Co., Ltd.
2014-11 – 2020-06 · Coronary Artery Disease
What this study did
Studied as part of a combination product (15)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (2)
Other / comorbidity
NCT01182649 · San Giuseppe Moscati Hospital
2007-03 – 2010-06 · Coronary Artery Disease, Coronary Atherosclerosis
What this study did
NCT01016041 · Maasstad Hospital
2007-02 – 2008-09 · Stable Angina, Unstable Angina, Acute Coronary Syndrome
What this study did
Phase 4 (9)
Other / comorbidity
NCT06769217 · Frisch Medical Device Private Limited
2023-01-01 – 2025-01-30 · Coronary Arterial Disease (CAD)
What this study did
NCT02377648 · Universita di Verona
2015-01 – 2020-12 · Cardiac Allograft Vasculopathy
What this study did
NCT01776567 · Northern Hospital, Australia
2012-07 – 2015-06 · Coronary Artery Disease
What this study did
NCT01711931 · University of Freiburg
2012-10 – 2013-12 · Coronary Artery Disease
What this study did
NCT01157455 · CCRF Consulting Co., Ltd.
2010-05 – 2013-06 · Coronary Artery Diseases
What this study did
NCT00598637 · Deutsches Herzzentrum Muenchen
2007-12 – 2013-02 · Coronary Disease
What this study did
NCT01684982 · San Giuseppe Moscati Hospital
2007-04 – 2012-06 · Acute Myocardial Infarction
What this study did
NCT01200693 · Catholic University of the Sacred Heart
2008-11 – 2012-03 · Coronary Artery Disease, Coronary Stenosis
What this study did
NCT01510509 · Hospital Universitario Infanta Cristina
started 2009-01 · Diabetes Mellitus, Percutaneous Coronary Intervention
What this study did
Early phase / not applicable (4)
Other / comorbidity
NCT07566091 · Jung-min Ahn
2026-10-06 – 2028-06-15 · Coronary Artery Disease
What this study did
NCT01735825 · University Hospital Ostrava
2012-01 – 2018-06 · Restenosis
What this study did
NCT01065519 · Universitaire Ziekenhuizen KU Leuven
2009-06 – 2016-01-14 · Coronary Artery Disease
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (3)
HR+/HER2- Metastatic Breast Cancer
NCT02376985 · Comprehensive Support Project for Oncology Research
2015-03-26 – 2018-10-16 · Breast Cancer
What this study did
Renal Cell Carcinoma
NCT01198158 · National Cancer Institute (NCI)
2010-09-15 – 2017-12-16 · Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
What this study did
Other / comorbidity
NCT03839940 · Alliance for Clinical Trials in Oncology
2019-06-03 – 2022-08-03 · Malignant Neoplasm
What this study did
Phase 2 (1)
HR+/HER2- Metastatic Breast Cancer
Early phase / not applicable (1)
Other / comorbidity
NCT01190241 · Amsterdam UMC, location VUmc
2010-08 – 2017-12 · Advanced Solid Tumors, Inoperable, Metastasis
What this study did

Competitive landscape

This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Everolimus: this drugApprovedSmall moleculemTOR (mTORC1) (inhibitor), mTOR kinasePartial signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
EpirubicinApprovedSmall moleculeTopoisomerase II / DNAPartial signal
NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
ExemestaneApprovedSmall moleculeAromataseReliable signal
NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88)
NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86).
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4)
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistPartial signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet graded
NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending
NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)Partial signal
NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001.
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 2Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
HRS-2189Phase 1/2UndisclosedKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
HRS-6208Phase 1/2UndisclosedCDK7not yet gradedNo reviewed efficacy summary in this indication
TegtociclibPhase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication
JNJ-101684362Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RAE346
—(overall)
Small moleculePI3Kα (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(61 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Everolimus to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (7)
December 2026 (7)
Phase 1Acute Myeloid Leukemia, Myelodysplastic SyndromeActive not recruiting
Est. primary completion 2026-12 · NCT00819546 · CT.gov ↗
What to watch
Phase 2Soft Tissue SarcomaActive not recruiting
Est. primary completion 2026-12 · NCT03114527 · CT.gov ↗
What to watch
Phase 1EpilepsyRecruiting
Est. primary completion 2026-12-01 · NCT07095933 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C MutationActive not recruiting
Est. primary completion 2026-12-17 · NCT04185883 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-27 · NCT05563220 · CT.gov ↗
What to watch
Phase 1ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement …Active not recruiting
Est. primary completion 2026-12-31 · NCT02321501 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT07435584 · CT.gov ↗
What to watch
2027 (18)
February 2027 (1)
Phase 3EpilepsyActive not recruiting
Est. primary completion 2027-02-26 · NCT02962414 · CT.gov ↗
What to watch
March 2027 (4)
Phase 1AgingRecruiting
Est. primary completion 2027-03 · NCT05949658 · CT.gov ↗
What to watch
Phase 1/2ProgeriaEnrolling by invitation
Est. primary completion 2027-03 · NCT02579044 · CT.gov ↗
What to watch
Phase 4Carcinoma, HepatocellularEnrolling by invitation
Est. primary completion 2027-03 · NCT02081755 · CT.gov ↗
What to watch
Phase 2Healthy, Osteopenia, Osteoporosis RiskRecruiting
Est. primary completion 2027-03-01 · NCT07191353 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Thyroid CancerActive not recruiting
Est. primary completion 2027-06 · NCT01141309 · CT.gov ↗
What to watch
July 2027 (2)
Phase 1Glioblastoma, Recurrent Disease, Recurrent GlioblastomaEnrolling by invitation
Est. primary completion 2027-07-01 · NCT05432518 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-22 · NCT07062965 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07937553 · CT.gov ↗
What to watch
September 2027 (2)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-09 · NCT06382948 · CT.gov ↗
What to watch
Phase 1/2AgingRecruiting
Est. primary completion 2027-09-01 · NCT06727305 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-10-25 · NCT05012371 · CT.gov ↗
What to watch
December 2027 (6)
Early phase / not applicableKidney Transplant Failure and RejectionRecruiting
Est. primary completion 2027-12-03 · NCT03955172 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12-27 · NCT06730672 · CT.gov ↗
What to watch
Phase 1Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High-Grade Glioma (HGG)Recruiting
Est. primary completion 2027-12-31 · NCT04485559 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT05508906 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05749588 · CT.gov ↗
What to watch
Early phase / not applicableKidney Transplant Infection, BK Virus InfectionActive not recruiting
Est. primary completion 2027-12-31 · NCT04542733 · CT.gov ↗
What to watch
2028 (18)
January 2028 (3)
Phase 2Malignant Solid NeoplasmsRecruiting
Est. primary completion 2028-01 · NCT02029001 · CT.gov ↗
What to watch
Phase 4CMV InfectionNot yet recruiting
Est. primary completion 2028-01 · NCT07570433 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-01-31 · NCT01217931 · CT.gov ↗
What to watch
February 2028 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-02 · NCT05573126 · CT.gov ↗
What to watch
March 2028 (1)
Phase 2Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1, Neuroendocrine Neoplasm …Active not recruiting
Est. primary completion 2028-03-30 · NCT03950609 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-05-01 · NCT07002177 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Liver TransplantRecruiting
Est. primary completion 2028-06-30 · NCT06280950 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1AgingRecruiting
Est. primary completion 2028-07 · NCT06658093 · CT.gov ↗
What to watch
August 2028 (4)
Phase 1Phase IB, Avutometinib, RAS Pathway, EndometrialRecruiting
Est. primary completion 2028-08-01 · NCT07318324 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-08-01 · NCT07900516 · CT.gov ↗
What to watch
Phase 2Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Carcinoma …Active not recruiting
Est. primary completion 2028-08-31 · NCT03008408 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-08-31 · NCT06680921 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid AdenocarcinomaActive not recruiting
Est. primary completion 2028-09-30 · NCT02397083 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Neoplasms of Bone and Articular Cartilage With Unspecified Anatomical SiteNot yet recruiting
Est. primary completion 2028-11-30 · NCT07619950 · CT.gov ↗
What to watch
December 2028 (4)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-12-18 · NCT07634601 · CT.gov ↗
What to watch
Phase 3Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2028-12-30 · NCT07165418 · CT.gov ↗
What to watch
Phase 2Neuroendocrine Tumors, Liver MetastasesNot yet recruiting
Est. primary completion 2028-12-31 · NCT07946627 · CT.gov ↗
What to watch
Early phase / not applicableMetastatic Sarcoma, Recurrent Sarcoma, Resectable SarcomaRecruiting
Est. primary completion 2028-12-31 · NCT04199026 · CT.gov ↗
What to watch
2029 (6)
January 2029 (1)
Phase 2Solid Tumor, Adult, Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-01-01 · NCT04803318 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2029-04-16 · NCT06994572 · CT.gov ↗
What to watch
May 2029 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-05-30 · NCT04802759 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Liver Allograft, Liver Diseases, Liver TransplantationRecruiting
Est. primary completion 2029-06-30 · NCT07739914 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma …Recruiting
Est. primary completion 2029-08-31 · NCT05843253 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-11 · NCT07937605 · CT.gov ↗
What to watch
2030 (7)
June 2030 (1)
Phase 1Liver TransplantRecruiting
Est. primary completion 2030-06-01 · NCT06832189 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Carcinom, HepatocellularNot yet recruiting
Est. primary completion 2030-07-01 · NCT06972758 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2/3Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease, Cerebellum Dysplastic Gangliocytoma, Bannayan Zonana Syndrome …Not yet recruiting
Est. primary completion 2030-09 · NCT07218575 · CT.gov ↗
What to watch
October 2030 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-10 · NCT05933395 · CT.gov ↗
What to watch
Phase 2Vascular Malformations, Arteriovenous Malformations, Venous Malformation, Lymphangioma, Nevus, Port-Wine, Hemangioendothelioma, HemangiomaNot yet recruiting
Est. primary completion 2030-10-31 · NCT07477548 · CT.gov ↗
What to watch
December 2030 (2)
Phase 4Heart TransplantNot yet recruiting
Est. primary completion 2030-12 · NCT06942156 · CT.gov ↗
What to watch
Phase 4Cutaneous Squamous Cell Carcinoma, Skin CancerRecruiting
Est. primary completion 2030-12-15 · NCT07426484 · CT.gov ↗
What to watch
2031 (2)
February 2031 (1)
Phase 1/2Pediatric CancerRecruiting
Est. primary completion 2031-02 · NCT02813135 · CT.gov ↗
What to watch
June 2031 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2031-06-02 · NCT07340541 · CT.gov ↗
What to watch
2033 (2)
February 2033 (1)
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2033-02-01 · NCT07407517 · CT.gov ↗
What to watch
June 2033 (1)
Phase 1Medulloblastoma Recurrent, MedulloblastomaNot yet recruiting
Est. primary completion 2033-06 · NCT07865130 · CT.gov ↗
What to watch
2038 (1)
December 2038 (1)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2038-12-31 · NCT05725200 · CT.gov ↗
What to watch

See the full readout calendar ↗